Bafna Pharmaceuticals Limited

As of June 30, 2026, Bafna Pharmaceuticals Limited carries a market capitalization of 5.08B, placing it among publicly traded companies globally. Its enterprise value stands at 5.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bafna Pharmaceuticals Limited has 23.66M shares outstanding.

As of June 30, 2026, Bafna Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 66.13.

As of June 30, 2026, Bafna Pharmaceuticals Limited trades at an EV/EBITDA multiple of 43.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 96.21 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.08B versus a market cap of 5.08B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 3.83M in revenue per employee across its workforce of 372.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bafna Pharmaceuticals Limited recorded an income tax benefit of -1.30M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 76.56M, leaving 77.86M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bafna Pharmaceuticals Limited's stock has gained approximately 220.53% over the past 52 weeks. The 50-day moving average sits at 334.20, while the 200-day moving average is 198.09.

Over the twelve months ended June 30, 2026, Bafna Pharmaceuticals Limited generated 1.43B in revenue and converted that into 77.86M in net income, yielding earnings per share of 3.25. EBITDA reached 117.61M, while operating income came in at 52.78M.

Over the twelve months ended June 30, 2026, Bafna Pharmaceuticals Limited posted a gross margin of 31.57, reflecting its pricing power and cost economics. The operating margin of 3.70 and net profit margin of 5.46 provide insight into operational efficiency.

Bafna Pharmaceuticals Limited's most recent stock split took place on August 26, 2019 with a 10:1 split ratio.